[go: up one dir, main page]

UY24546A1 - Derivados indolicos utiles para terapia - Google Patents

Derivados indolicos utiles para terapia

Info

Publication number
UY24546A1
UY24546A1 UY24546A UY24546A UY24546A1 UY 24546 A1 UY24546 A1 UY 24546A1 UY 24546 A UY24546 A UY 24546A UY 24546 A UY24546 A UY 24546A UY 24546 A1 UY24546 A1 UY 24546A1
Authority
UY
Uruguay
Prior art keywords
alkyl
formula
tetrazol
alkenyl
compounds
Prior art date
Application number
UY24546A
Other languages
English (en)
Inventor
Kim James
David James Rawson
Kevin Neil Dack
Roger Peter Dickinson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY24546A1 publication Critical patent/UY24546A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Esta invención se refiere a derivados indólicos de la fórmula I, útiles en el tratamiento de diversas enfermedades incluyendo la reestenosis, (la insuficiencia renal, y la hipertensión pulmonar), y a formulaciones farmacéuticas que contienen dichos compuestos. Se trata de compuestos de fórmula l (como por ejemplo: Acido2- [3-(1-etil-6-metoxicrbonil)indolil]-2-(3,4-metilen-dioxifenil)acético) donde R1 y R2 son sustituyentes opcionales y representan independientemente alquilo, alquenilo, alquinilo, halógeno, perfluoroalquilo, etc; R3 representa H, alquilo, alquenilo, (CH2)pCN, (CH2)mHet, SO2NR7R8, etc; R4 representan H o alquilo; R5 se selecciona entre H o OH; y R6 significa entre fenilo opcionalmente condensado con un anillo heterocíclico saturado de 5 ó 6 elementos, que contiene 1 o 2 heteroátomos seleccionados entre N, S y O, estando el grupo en su totalidad opcionalmente sustituido con uno o más grupos; Z representa CO2H, CONH(tetrazol-5-ilo), CONHSO2O(alquilo), CO2Ar, CO2(alquilo), tetrazol-5-ilo, CONHSO2Ar, CONHSO2(alquilo). Una formulación farmacéutica que contiene un compuesto de fórmula l, o un derivado farmacéuticamente aceptable del mismo y un adyuvante, diluyente o vehículo farmacéuticamente aceptable.
UY24546A 1996-05-09 1997-05-07 Derivados indolicos utiles para terapia UY24546A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609641.7A GB9609641D0 (en) 1996-05-09 1996-05-09 Compounds useful in therapy
PCT/EP1997/001882 WO1997043260A1 (en) 1996-05-09 1997-04-11 Indole derivatives useful as endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
UY24546A1 true UY24546A1 (es) 2000-09-29

Family

ID=10793387

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24546A UY24546A1 (es) 1996-05-09 1997-05-07 Derivados indolicos utiles para terapia

Country Status (42)

Country Link
US (4) US6017945A (es)
EP (1) EP0901470B1 (es)
JP (1) JP3245179B2 (es)
KR (1) KR100331217B1 (es)
CN (1) CN1124262C (es)
AP (1) AP830A (es)
AR (1) AR007030A1 (es)
AT (1) ATE263151T1 (es)
AU (1) AU717849B2 (es)
BG (1) BG102873A (es)
BR (1) BR9709072A (es)
CA (1) CA2253876A1 (es)
CO (1) CO4650036A1 (es)
CZ (1) CZ292928B6 (es)
DE (1) DE69728392T2 (es)
DK (1) DK0901470T3 (es)
DZ (1) DZ2227A1 (es)
EA (1) EA001471B1 (es)
ES (1) ES2218675T3 (es)
GB (1) GB9609641D0 (es)
HN (1) HN1997000058A (es)
HR (1) HRP970249B1 (es)
HU (1) HUP9901245A3 (es)
ID (1) ID16878A (es)
IL (1) IL125903A0 (es)
IS (1) IS1856B (es)
MA (1) MA26428A1 (es)
NO (1) NO312547B1 (es)
NZ (1) NZ332640A (es)
OA (1) OA10896A (es)
PE (1) PE65098A1 (es)
PL (1) PL329725A1 (es)
PT (1) PT901470E (es)
SI (1) SI0901470T1 (es)
SK (1) SK150398A3 (es)
TN (1) TNSN97078A1 (es)
TR (1) TR199802269T2 (es)
TW (1) TW491838B (es)
UA (1) UA50767C2 (es)
UY (1) UY24546A1 (es)
WO (1) WO1997043260A1 (es)
ZA (1) ZA973963B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722287D0 (en) * 1997-10-22 1997-12-17 Pfizer Ltd Compounds useful in therapy
SK288365B6 (sk) * 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
US20050203166A1 (en) * 2000-06-30 2005-09-15 Cancer Research Technology Limited Indole-3-acetic acid derivatives
GB0016162D0 (en) * 2000-06-30 2000-08-23 Cancer Res Campaign Tech Indole-3-acetic acid derivatives
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
JP2006510673A (ja) 2002-12-10 2006-03-30 ワイス プラスミノゲンアクティベータインヒビター1(pai−1)のインヒビターとしての、アリール、アリールオキシ、および、アルキルオキシ置換1h−インドール−3−イルグリオキシル酸誘導体
DE60327550D1 (de) 2002-12-10 2009-06-18 Wyeth Corp Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
DE60306547T2 (de) 2002-12-10 2007-06-28 Wyeth Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen-aktivator
DE60306548T2 (de) 2002-12-10 2007-06-21 Wyeth Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US20060235222A1 (en) * 2003-01-22 2006-10-19 Eli Lilly And Company Indole-derivative modulators of steroid hormone nuclear receptors
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
JP2005109006A (ja) * 2003-09-29 2005-04-21 Tdk Corp 高電圧貫通型コンデンサ及びマグネトロン
HN2004000536A (es) * 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
AU2005277137A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
JP2008510815A (ja) 2004-08-23 2008-04-10 ワイス 血栓症および心臓血管疾患の治療にて有用な調節剤であるプラスミノゲン活性化因子阻害剤1型(pai−1)としてのオキサゾロ−ナフチル酸
CA2577846A1 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
CN101263115A (zh) 2005-08-17 2008-09-10 惠氏公司 经取代吲哚和其用途
AU2007237874A1 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
DE102008030207A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California Compounds for increasing neural plasticity
CN106674065A (zh) * 2016-12-07 2017-05-17 贵州大学 一种5‑卤代‑2‑烷氧基‑4‑甲苯磺酰氯制备方法
GB201817038D0 (en) * 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス,インク. フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
CN117263832B (zh) * 2023-08-18 2026-02-03 辽宁龙田化工科技有限公司 一种2-氯-4-甲磺酰基苯甲酸合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297890A (es) * 1962-09-14
DE1950346B2 (de) * 1968-10-08 1973-06-28 Sumitomo Chemical Co 2-indolylessigsaeureverbindungen und diese verbindungen enthaltende arzneipraeparate
US4397079A (en) * 1981-03-30 1983-08-09 International Business Machines Corp. Process for improving the yield of integrated devices including Schottky barrier diodes
US5245046A (en) * 1988-11-14 1993-09-14 The Upjohn Company α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
ATE136026T1 (de) 1990-09-10 1996-04-15 Rhone Poulenc Rorer Int Substituierte bizyklische arylderivate mit selektiver leukotrien b4 antagonistischer wirkung
ZA939516B (en) * 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
PT617001E (pt) * 1993-03-19 2000-06-30 Merck & Co Inc Derivados do acido fenoxifenilacetico
GB9317096D0 (en) * 1993-08-17 1993-09-29 Pfizer Ltd Indoles

Also Published As

Publication number Publication date
AU2697897A (en) 1997-12-05
HUP9901245A3 (en) 2002-01-28
JPH11508285A (ja) 1999-07-21
JP3245179B2 (ja) 2002-01-07
HRP970249A2 (en) 1998-06-30
ID16878A (id) 1997-11-20
US20010014677A1 (en) 2001-08-16
GB9609641D0 (en) 1996-07-10
HUP9901245A2 (hu) 1999-08-30
BG102873A (en) 1999-11-30
TR199802269T2 (xx) 2001-12-21
CA2253876A1 (en) 1997-11-20
TW491838B (en) 2002-06-21
TNSN97078A1 (fr) 2005-03-15
DK0901470T3 (da) 2004-07-12
IL125903A0 (en) 1999-04-11
AP9700982A0 (en) 1997-07-31
NO985225L (no) 1998-11-09
AR007030A1 (es) 1999-10-13
HK1019149A1 (en) 2000-01-14
AU717849B2 (en) 2000-04-06
HRP970249B1 (en) 2003-06-30
US6017945A (en) 2000-01-25
HN1997000058A (es) 1997-06-26
PT901470E (pt) 2004-07-30
PL329725A1 (en) 1999-04-12
ZA973963B (en) 1998-11-09
AP830A (en) 2000-05-03
NO985225D0 (no) 1998-11-09
NO312547B1 (no) 2002-05-27
CN1124262C (zh) 2003-10-15
PE65098A1 (es) 1998-10-29
EA199800908A1 (ru) 1999-06-24
SK150398A3 (en) 1999-03-12
CZ292928B6 (cs) 2004-01-14
SI0901470T1 (en) 2004-08-31
WO1997043260A1 (en) 1997-11-20
US6136843A (en) 2000-10-24
IS4838A (is) 1998-08-28
EP0901470B1 (en) 2004-03-31
CN1216531A (zh) 1999-05-12
EA001471B1 (ru) 2001-04-23
DZ2227A1 (fr) 2002-12-25
MA26428A1 (fr) 2004-12-20
CO4650036A1 (es) 1998-09-03
BR9709072A (pt) 1999-08-03
CZ358298A3 (cs) 1999-08-11
US6306852B1 (en) 2001-10-23
KR100331217B1 (ko) 2002-05-09
UA50767C2 (uk) 2002-11-15
US6384070B2 (en) 2002-05-07
IS1856B (is) 2003-02-21
ATE263151T1 (de) 2004-04-15
NZ332640A (en) 2001-03-30
OA10896A (en) 2001-10-11
EP0901470A1 (en) 1999-03-17
ES2218675T3 (es) 2004-11-16
DE69728392D1 (de) 2004-05-06
KR20000010879A (ko) 2000-02-25
DE69728392T2 (de) 2005-01-13

Similar Documents

Publication Publication Date Title
UY24546A1 (es) Derivados indolicos utiles para terapia
UY23657A1 (es) Procedimiento para la preparacion de derivados de indol
DK419086D0 (da) Heterocykliske substituerede indoler, mellemprodukter, fremgangsmaader til fremstilling heraf og laegemidler
AR016429A1 (es) Compuesto derivado de acido hidroxamico como inhibidores de metaloproteasa de matriz (mmp), composiciones farmaceuticas y formulaciones veterinarias, usopara la preparacion de composiciones y formulaciones, compuesto intermediario, procedimiento de preparacion del compuesto.
AR005166A1 (es) Compuestos de quinolina y quinazolina, su uso, un procedimiento para producirlos, formulaciones farmaceuticas que los incluyen y compuesto utilescomo intermedios en dicho procedimiento.
RU2007138937A (ru) Производные 1-бензилиндол-2-карбоксамида
PE20040698A1 (es) Derivados de isoindolina
ES2195382T3 (es) Compuestos indolcarboxilicos y su uso como compuestos farmaceuticos.
AR015036A1 (es) Derivados de indolilo antisicoticos, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
DE50304030D1 (de) Verfahren zur Herstellung von 5-Nitrobenzofuranen
FI911885A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 2,9-disubstituoitujen 3-/2-/4-(6-fluori-1,2-bentsisoksatsol-3-yyli)-piperidinyyli/etyyli/-4H-pyrido/1,2-a/pyrimidin-4-onien valmistamiseksi
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
AR036864A1 (es) Uso de compuestos de acido benzacepin-n-acetico, y procedimiento para la preparacion de dichos compuestos
US5591866A (en) (1H-indol-1-yl)-2-(amino)acetamide derivatives and preparation thereof
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
NO177995C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 1,3-dioksanderivater
AR023111A1 (es) Derivados de sulfonamida utiles como antagonistas del receptor 5-ht7, un procedimiento para su preparacion y composicion farmaceutica que los comprenden
ECSP972103A (es) Derivados indolicos utiles para terapia
AR047628A1 (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa
ES2069967T3 (es) 5-piperazinilalquil-1,5-benzotiazepinonas utiles como antagonistas del calcio.
AR002715A1 (es) Derivados de piperazina y piperazinona heterociclos substituidos particularmente utiles como antagonistas de los receptores de taquikinina,composicion farmaceutica que incluye uno de dichos derivados, uso de dichos compuestos en la preparacion de las composiciones y procedimiento para la preparacion de los derivados
NO883263D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazol-derivater.
NO803547L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-fenylamino-imidazolin-derivater
PE20050139A1 (es) Compuestos derivados de acidos hidroxamicos y composiciones farmaceuticas
ATE258934T1 (de) Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20170507